Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/5295
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFıratlıgil, Burcu-
dc.contributor.authorBiray Avcı, Çığır-
dc.contributor.authorBaran, Yusuf-
dc.date.accessioned2017-04-12T13:42:26Z-
dc.date.available2017-04-12T13:42:26Z-
dc.date.issued2013-04-
dc.identifier.citationFıratlıgil, B., Biray Avcı, Ç., and Baran, Y. (2013). miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells. Journal of B.U.ON., 18(2), 437-441.en_US
dc.identifier.issn1107-0625-
dc.identifier.urihttp://hdl.handle.net/11147/5295-
dc.description.abstractIn this study we examined the expression levels of miR-17 which possesses oncogenic activities through downregulation of CDKN1A, p21 and E2F1 tumor suppressor genes, in imatinib sensitive and resistant chronic myeloid leukemia (CML) cells. On the other hand, we also determined the expression levels of miR-17 in response to tyrosine kinase inhibitors imatinib, nilotinib and dasatinib used for the treatment of CML. Methods: The expression profiles of miR-17 were analysed by Stem-Loop reverse transcription (RT) polymerase chain reaction (PCR). Results: The results revealed significant increase in the expression levels of miR-17 in imatinib sensitive and resistant cells compared to peripheral blood mononuclear cells (PBMCs). On the other hand, significant decrease was observed in miR-17 levels in response to imatinib, nilotinib and dasatinib. Conclusion: These results may imply that miR-17 can be used for diagnosis and treatment of CML.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkeyen_US
dc.language.isoenen_US
dc.publisherZerbinis Medical Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic myeloid leukemiaen_US
dc.subjectDasatiniben_US
dc.subjectDrug resistanceen_US
dc.subjectImatiniben_US
dc.subjectMicroRNAsen_US
dc.subjectNilotiniben_US
dc.titlemiR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cellsen_US
dc.typeArticleen_US
dc.authoridTR119193en_US
dc.institutionauthorFıratlıgil, Burcu-
dc.institutionauthorBaran, Yusuf-
dc.departmentİzmir Institute of Technology. Molecular Biology and Geneticsen_US
dc.identifier.volume18en_US
dc.identifier.issue2en_US
dc.identifier.startpage437en_US
dc.identifier.endpage441en_US
dc.identifier.wosWOS:000322750700020en_US
dc.identifier.scopus2-s2.0-84879578050en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.pmid23818358en_US
dc.identifier.scopusqualityN/A-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.cerifentitytypePublications-
item.openairetypeArticle-
crisitem.author.dept04.03. Department of Molecular Biology and Genetics-
crisitem.author.dept04.03. Department of Molecular Biology and Genetics-
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File Description SizeFormat 
5295.pdfMakale1.17 MBAdobe PDFThumbnail
View/Open
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

8
checked on Oct 4, 2024

WEB OF SCIENCETM
Citations

7
checked on Oct 5, 2024

Page view(s)

230
checked on Sep 30, 2024

Download(s)

86
checked on Sep 30, 2024

Google ScholarTM

Check





Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.